- Home
- GRI vs INM Comparison
GRI vs INM Comparison
Compare GRI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- INM
- Stock Information
- Founded
- GRI 2018
- INM 1981
- Country
- GRI United States
- INM Canada
- Employees
- GRI N/A
- INM N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- GRI Health Care
- INM Health Care
- Exchange
- GRI Nasdaq
- INM Nasdaq
- Market Cap
- GRI 3.2M
- INM 3.2M
- IPO Year
- GRI N/A
- INM N/A
- Fundamental
- Price
- GRI $1.38
- INM $2.87
- Analyst Decision
- GRI Strong Buy
- INM
- Analyst Count
- GRI 2
- INM 0
- Target Price
- GRI $22.00
- INM N/A
- AVG Volume (30 Days)
- GRI 358.1K
- INM 4.1M
- Earning Date
- GRI 05-15-2025
- INM 05-12-2025
- Dividend Yield
- GRI N/A
- INM N/A
- EPS Growth
- GRI N/A
- INM N/A
- EPS
- GRI N/A
- INM N/A
- Revenue
- GRI N/A
- INM $4,920,990.00
- Revenue This Year
- GRI N/A
- INM N/A
- Revenue Next Year
- GRI N/A
- INM N/A
- P/E Ratio
- GRI N/A
- INM N/A
- Revenue Growth
- GRI N/A
- INM N/A
- 52 Week Low
- GRI $1.10
- INM $1.72
- 52 Week High
- GRI $66.30
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- GRI 39.90
- INM 50.24
- Support Level
- GRI $1.24
- INM $2.74
- Resistance Level
- GRI $1.49
- INM $3.45
- Average True Range (ATR)
- GRI 0.12
- INM 0.70
- MACD
- GRI 0.07
- INM 0.03
- Stochastic Oscillator
- GRI 59.52
- INM 9.40
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.